+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study

Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study

Therapeutic Advances in Gastroenterology 10(2): 199-206

Granulocyte and monocyte apheresis (GMA) has shown therapeutic efficacy in active ulcerative colitis (UC). We thought that in patients with pouchitis after proctocolectomy for UC, GMA might produce immunological effects in the intestinal mucosa, and improve clinical symptoms. This prospective study was to evaluate the efficacy of GMA for antibiotic-refractory pouchitis after proctocolectomy for UC. A total of 13 patients with pouchitis disease activity index (PDAI) > 7 unresponsive to 2 weeks of antibiotic therapy were included. All patients received 10 GMA sessions at 2 sessions/week over 5 consecutive weeks. The primary endpoints were response (a decrease of ⩾3 points in the PDAI) and remission (PDAI < 4). Secondary endpoints included reduction of white blood cells (WBCs), C-reactive protein (CRP), faecal markers (calprotectin and lactoferrin), reduction of the PDAI endoscopic subscore, and GMA safety. The median PDAI score was significantly decreased from 11 (range, 9-15) at entry to 9 (range, 6-13) after the GMA therapy (p = 0.02). A total of six patients (46%) responded to the treatment, but none achieved remission. The median endoscopic subscore (maximum: 6) was 5 (range, 4-6) at entry and 5 (range, 1-6) after the treatment (p = 0.10). None of the laboratory markers (WBCs, CRP, faecal calprotectin and lactoferrin) significantly changed during the treatment. Transient adverse events (AEs) were observed in two patients (15%), dyspnoea in one and headache in one. The AEs were not serious, and all patients completed the 10 GMA sessions. GMA has a good safety profile, but its efficacy appears to be limited in the management of chronic refractory pouchitis. However, a large controlled study should be conducted to evaluate the efficacy of GMA therapy in patients with pouchitis at an earlier clinical stage, before the disease has become refractory to conventional medical therapy.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 059667630

Download citation: RISBibTeXText

PMID: 28203278

DOI: 10.1177/1756283x16679348

Related references

Granulocyte and monocyte adsorption apheresis in Korean conventional treatment-refractory patients with active ulcerative colitis: a prospective open-label multicenter study. Korean Journal of Gastroenterology 45(1): 34-44, 2005

Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World Journal of Gastroenterology 11(44): 7001-7006, 2005

Granulocyte apheresis for pouchitis with arthritis and pyoderma gangrenosum after restorative proctocolectomy for ulcerative colitis: a case report. Inflammatory Bowel Diseases 11(8): 780-781, 2005

Sa1197 Factors Associated With Treatment Outcome, and Long-Term Prognosis of Patients With Ulcerative Colitis Undergoing Adsorptive Granulocyte/Monocyte Apheresis: A Prospective Multicentre Investigation. Gastroenterology 148(4): S-254, 2015

Sa1919 Quality of Life After Remission Induction by Adsorptive Granulocyte/Monocyte Apheresis Predicts the Long-Term Prognosis of Ulcerative Colitis Patients: A Prospective Multicentre Study. Gastroenterology 142(5): S-359-S-360, 2012

A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis. Journal of Gastroenterology 43(1): 51-56, 2008

Adjunct antibiotic combination therapy for steroid-refractory or -dependent ulcerative colitis: an open-label multicentre study. Alimentary Pharmacology and Therapeutics 39(9): 949-956, 2014

Comparison of the efficacy of granulocyte and monocyte/macrophage adsorptive apheresis and leukocytapheresis in active ulcerative colitis patients: a prospective randomized study. European Journal of Gastroenterology and Hepatology 20(7): 629-633, 2008

W1327 Long Term Efficacy of Granulocyte-Monocyte-Apheresis in Ulcerative Colitis. the Italian Registry of Therapeutic Apheresis. Gastroenterology 138(5): S-700, 2010

Dose-intensified granulocyte-monocyte apheresis in therapy refractory ulcerative colitis. Artificial Organs 39(2): 187-192, 2015

Clinical Features of Refractory Pouchitis with Penetrating Lesions and the Efficacy of Infliximab Treatment for Patients with Ulcerative Colitis after Restorative Proctocolectomy. Digestion 92(3): 147-155, 2015

Mucosal features and granulocyte-monocyte-apheresis in steroid-dependent/refractory ulcerative colitis. Digestive and Liver Disease 38(6): 389-394, 2006

Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis. Scandinavian Journal of Gastroenterology 53(4): 442-448, 2018

Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. Journal of Crohn's and Colitis 12(6): 687-694, 2018

Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresis. World Journal of Gastroenterology 17(14): 1831-1835, 2011